Table 2 Chemotherapy regimens received
| Â | N | % |
|---|---|---|
First-line | 83 | 100 |
 - FOLFIRINOX | 42 | 50.6 |
 - nabPGem | 41 | 49.4 |
 - Death after 1st-line or not | 16 | 19.3 |
 - suitable for 2nd-line |  |  |
 - too early (1st-line ongoing) | 3 | 3.6 |
Second-line | 64 | 100 |
 - FOLFIRINOX | 13 | 20.3 |
 - nabPGem | 35 | 54.7 |
 - Nal-IRI | 11 | 17.2 |
 - FOLFOX | 2 | 3.1 |
 - FOLFIRI | 2 | 3.1 |
 - Gem/Erlotinib | 1 | 1.6 |
 - Death after 2nd-line or not suitable for 3rd-line | 19 | 29.7 |
 - too early (2nd-line ongoing) | 10 | 15.6 |
Third-line | 35 | 100 |
 - FOLFIRINOX re-induction | 8 | 22.9 |
 - nabPGem | 6 | 17.1 |
 - FOLFOX | 2 | 5.7 |
 - Gem/Erlotinib | 11 | 31.4 |
 - nab-Pacl/5-FU | 1 | 2.9 |
 - nal-IRI | 5 | 14.3 |
 - FOLFIRI | 3 | 8.6 |
 - nal-IRI/Erlotinib | 2 | 5.7 |
> Fourth-line | 17 | Â |